Xenon Pharmaceuticals - XENE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $59.11
  • Forecasted Upside: 58.69%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$37.25
▼ -0.79 (-2.08%)

This chart shows the closing price for XENE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Xenon Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for XENE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for XENE

Analyst Price Target is $59.11
▲ +58.69% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Xenon Pharmaceuticals in the last 3 months. The average price target is $59.11, with a high forecast of $65.00 and a low forecast of $50.00. The average price target represents a 58.69% upside from the last price of $37.25.

This chart shows the closing price for XENE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 9 contributing investment analysts is to buy stock in Xenon Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/20/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/18/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/17/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/16/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/15/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$62.00 ➝ $62.00Low
5/10/2024CitigroupLower TargetBuy ➝ Buy$62.00 ➝ $60.00Low
5/10/2024WedbushLower TargetOutperform ➝ Outperform$51.00 ➝ $50.00Low
4/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$62.00Low
4/10/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$65.00Low
3/1/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$56.00 ➝ $55.00Low
3/1/2024WedbushBoost TargetOutperform ➝ Outperform$46.00 ➝ $51.00Low
3/1/2024Needham & Company LLCBoost TargetBuy ➝ Buy$50.00 ➝ $62.00N/A
1/4/2024CitigroupInitiated CoverageBuy$62.00Low
1/2/2024Bank of AmericaBoost TargetBuy ➝ Buy$52.00 ➝ $56.00Low
12/19/2023JPMorgan Chase & Co.Boost TargetOutperform$54.00 ➝ $59.00Low
12/18/2023Stifel NicolausBoost TargetBuy ➝ Buy$53.00 ➝ $62.00Low
12/8/2023Robert W. BairdInitiated CoverageOutperform$63.00Low
11/28/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$51.00 ➝ $56.00Low
11/9/2023WedbushLower TargetOutperform ➝ Outperform$47.00 ➝ $46.00Low
10/24/2023Cantor FitzgeraldReiterated RatingOverweightLow
9/22/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$51.00Low
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$58.00Low
8/10/2023WedbushReiterated RatingOutperform ➝ Outperform$47.00Low
8/10/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$50.00Low
5/10/2023Stifel NicolausBoost Target$52.00 ➝ $53.00Low
4/25/2023JPMorgan Chase & Co.Reiterated RatingTop PickLow
4/25/2023Cantor FitzgeraldInitiated CoverageOverweight$58.00Low
4/21/2023Needham & Company LLCReiterated RatingBuy$50.00Low
3/22/2023Royal Bank of CanadaReiterated RatingOutperform$51.00Low
3/2/2023Needham & Company LLCBoost TargetBuy$48.00 ➝ $50.00Low
1/31/2023Royal Bank of CanadaBoost TargetOutperform$49.00 ➝ $51.00Low
1/4/2023JPMorgan Chase & Co.Boost Target$52.00 ➝ $54.00Low
12/14/2022The Goldman Sachs GroupInitiated CoverageBuy$60.00Low
12/12/2022CowenInitiated CoverageOutperformLow
12/12/2022CowenInitiated CoverageOutperformLow
11/28/2022Wells Fargo & CompanyInitiated CoverageOverweight$50.00Low
11/11/2022GuggenheimLower TargetBuy$53.00 ➝ $49.00Low
10/18/2022Raymond JamesInitiated CoverageOutperform$52.00Low
10/11/2022Royal Bank of CanadaBoost TargetOutperform$46.00 ➝ $49.00Low
8/29/2022Bank of AmericaInitiated CoverageBuy$45.00Low
8/11/2022SVB LeerinkBoost TargetOutperform$40.00 ➝ $46.00Low
8/10/2022WedbushBoost Target$41.00 ➝ $50.00Low
7/21/2022JPMorgan Chase & Co.Initiated CoverageOverweight$55.00Low
6/27/2022WedbushLower TargetOutperform$47.00 ➝ $41.00Low
3/2/2022William BlairReiterated RatingOutperformLow
3/2/2022WedbushReiterated RatingOutperformLow
11/11/2021SVB LeerinkBoost TargetOutperform ➝ Outperform$34.00 ➝ $40.00High
10/28/2021Royal Bank of CanadaInitiated CoverageOutperform$43.00High
10/4/2021Needham & Company LLCBoost TargetBuy$25.00 ➝ $48.00High
10/4/2021GuggenheimBoost TargetBuy$30.00 ➝ $45.00High
5/13/2021SVB LeerinkReiterated RatingBuy$28.00High
3/5/2021William BlairReiterated RatingBuyLow
3/2/2021SVB LeerinkBoost TargetOutperform$25.00 ➝ $28.00High
3/2/2021Needham & Company LLCBoost TargetBuy$22.00 ➝ $25.00High
2/25/2021William BlairReiterated RatingOutperformLow
10/2/2020SVB LeerinkInitiated CoverageOutperform$22.00High
8/13/2020Bloom BurtonReiterated RatingBuy$25.00Medium
7/20/2020Needham & Company LLCInitiated CoverageBuy$22.00High
5/31/2020Jefferies Financial GroupInitiated CoverageBuy$16.00 ➝ $23.00High
5/22/2020William BlairReiterated RatingBuyHigh
3/24/2020WedbushInitiated CoverageOutperform$23.00Low
1/8/2020William BlairInitiated CoverageOutperformHigh
9/20/2019GuggenheimInitiated CoverageBuy$25.00High
(Data available from 6/14/2019 forward)

News Sentiment Rating

1.25 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
11/17/2023
  • 8 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 6 very negative mentions
12/17/2023
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/16/2024
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/15/2024
  • 19 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/16/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/15/2024
  • 7 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/15/2024
  • 17 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/14/2024

Current Sentiment

  • 17 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Xenon Pharmaceuticals logo
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.
Read More

Today's Range

Now: $37.25
Low: $36.57
High: $37.75

50 Day Range

MA: $40.35
Low: $37.68
High: $43.75

52 Week Range

Now: $37.25
Low: $27.99
High: $50.99

Volume

273,938 shs

Average Volume

385,251 shs

Market Capitalization

$2.81 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Frequently Asked Questions

What sell-side analysts currently cover shares of Xenon Pharmaceuticals?

The following Wall Street analysts have issued research reports on Xenon Pharmaceuticals in the last year: Bank of America Co., Cantor Fitzgerald, Citigroup Inc., JPMorgan Chase & Co., Needham & Company LLC, Robert W. Baird, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, and Wedbush.
View the latest analyst ratings for XENE.

What is the current price target for Xenon Pharmaceuticals?

9 Wall Street analysts have set twelve-month price targets for Xenon Pharmaceuticals in the last year. Their average twelve-month price target is $59.11, suggesting a possible upside of 58.7%. Cantor Fitzgerald has the highest price target set, predicting XENE will reach $65.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $50.00 for Xenon Pharmaceuticals in the next year.
View the latest price targets for XENE.

What is the current consensus analyst rating for Xenon Pharmaceuticals?

Xenon Pharmaceuticals currently has 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XENE will outperform the market and that investors should add to their positions of Xenon Pharmaceuticals.
View the latest ratings for XENE.

What other companies compete with Xenon Pharmaceuticals?

How do I contact Xenon Pharmaceuticals' investor relations team?

Xenon Pharmaceuticals' physical mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company's listed phone number is (604) 484-3300 and its investor relations email address is [email protected]. The official website for Xenon Pharmaceuticals is www.xenon-pharma.com. Learn More about contacing Xenon Pharmaceuticals investor relations.